Drug pricing
Featured Topics
Lead story
Other featured articles
-
Who Is Really Driving Up Insulin Costs?
In the long term, capping insulin payments at $35 a month is just shuffling the deck rather than changing the game of insulin costs.
Posted in -
Pharmacy Switching in Response to Preferred Pharmacy Networks in Medicare Part D
Researchers evaluate the effects of preferred pharmacy networks—a tool that Medicare Part D plans have recently adopted to steer patients to lower cost pharmacies—on the use of preferred pharmacies and factors underlying beneficiaries’ decisions on whether to switch to preferred pharmacies.
Posted in -
New Evidence Suggests a Lack of Cost-Shifting in Prescription Drug Markets
Recent legislative efforts to regulate drug prices have reignited debates about the interaction between price setting in public insurance programs and commercial market spending.
Posted in -
The Price of Insulin, Explained
This animation explains research by Schaeffer Center experts that offers one of the most comprehensive looks at the insulin distribution chain and shows which players are profiting, and by how much, from selling insulin.
Posted in
About this section
High pharmaceutical prices may garner headlines, but innovation must be appropriately incentivized to help solve healthcare’s intractable challenges. The Schaeffer Center connects industry, the academy and government to support the scientific and technological creativity that saves and improves lives — and spurs economic growth.
Our Experts On Drug pricing
Our Work In Drug pricing
-
Middlemen, Not Drug Companies, Are Pushing Up Insulin Prices, and Congress Doesn’t Have the Right Plan to Fight Back
Congress should take advantage of the current political climate and start reining in the intermediaries in the drug distribution system.
Categorized in -
How Did the Public U.S. Drugmakers’ Sales, Expenses and Profits Change Over Time?
Understanding what drives pharmaceutical firms’ revenue growth is critical to developing evidence-based policies that curb drug costs without reducing the industry’s innovations.
Categorized in -
Estimation of the Share of Net Expenditures on Insulin Captured by US Manufacturers, Wholesalers, Pharmacy Benefit Managers, Pharmacies, and Health Plans From 2014 to 2018
Recent US media and policy attention on insulin affordability has focused on the role of manufacturers in setting prices; however, the role of other drug distribution intermediaries in determining prices has received less attention.
Categorized in -
More than Half of Insulin Expenditures Going to Middlemen, New USC Schaeffer Study Finds
Schaeffer research offers one of the most comprehensive looks at the insulin distribution chain and shows which players are profiting, and by how much, from selling insulin.
Categorized in -
Untangling the Price of Insulin
Despite its discovery nearly 100 years ago, insulin’s list price has been going up, not down. New Schaeffer Center research analyzes the flow of money across all distribution system participants—manufacturers, wholesalers, pharmacies, pharmacy benefit managers (PBMs), and health plans.
-
The 340B Drug Pricing Program: Background, Ongoing Challenges and Recent Developments
The 340B Drug Pricing Program allows eligible healthcare clinics and hospitals (“covered entities”) to purchase outpatient drugs at a 20-50% discount.
Categorized in